16th Aug 2018 07:00
For immediate release | 16 August 2018 |
Verseon Corporation
("Verseon" or the "Company")
Change of Adviser
Fremont, Calif.- Verseon (AIM:VSN), a technology-based pharmaceutical company employing a computer-driven platform to develop a diverse drug pipeline, today announces the appointment of Arden Partners plc as nominated adviser and joint broker to the Company with immediate effect.
- Ends -
For further information, please contact:
Verseon Corporation | www.verseon.com |
Sebastian Wykeham | +1 (510) 225 9000 |
| |
Arden Partners (NOMAD and Joint Broker) |
|
Ruari McGirr / Maria Gomez De Olea
| +44 (0) 20 7614 5900 |
Cantor Fitzgerald Europe (Joint Broker) |
|
Marc Milmo / Phil Davies | +44 (0) 20 7894 7000 |
For financial and business media enquiries, please contact
Buchanan Communications Ltd (PR Advisers) |
|
Henry Harrison-Topham / Jamie Hooper | +44 (0) 20 7466 5000 |
About Verseon
Verseon Corporation (www.verseon.com, AIM: VSN) is a technology-based pharmaceutical company that pairs a proprietary, computational drug discovery platform with a comprehensive in-house chemistry and biology workflow to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.
Related Shares:
VERS.L